To Evaluate the Efficacy and Safety of Afatinib for Advanced ALTRK-negative ESCC
- Status
- RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Irinotecan
Related studies linked through entity extraction aliases.
Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE2
PD-1 Antibody Combined With mXELIRI Versus mXELIRI in the Second-line Setting for ESCC
- Status
- RECRUITING
- Phase
- PHASE3
The Efficacy and Safety of Fluzoparib Plus Irinotecan as Second-line Treatment in Patients With Homologous Recombination Deficiency (HRD) Metastatic Colorectal Cancer.
- Status
- UNKNOWN
- Phase
- PHASE2
SC0245 and Irinotecan in Treating Patients With Relapsed Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM Patients
- Status
- RECRUITING
- Phase
- PHASE2
Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Combination Therapy in Cancers With Mutations in DNA Repair Genes
- Status
- RECRUITING
- Phase
- PHASE1
Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer
- Status
- TERMINATED
- Phase
- PHASE2
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
- Status
- RECRUITING
- Phase
- PHASE3
Camrelizumab Combined With Irinotecan or Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
AD HOC Trial: Artificial Intelligence-Based Drug Dosing In Hepatocellular Carcinoma
- Status
- RECRUITING
- Phase
- PHASE2
Fruquintinib Plus Irinotecan in the Treatment of Advanced Gastric Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Phase I Dose Escalation and Pharmacokinetics Clinical Trial of Mitoxantrone Hydrochloride Liposome in Children With Relapsed and Refractory Lymphoma and Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Surufatinib Combined With Irinotecan as a Second-line Treatment for Small Cell Lung Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Study Investigating the Association of NP137 With mFOLFIRINOX in Locally Advanced Pancreatic Ductal Adenocarcinoma
- Status
- COMPLETED
- Phase
- PHASE1
A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer
- Status
- TERMINATED
- Phase
- PHASE2